• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用全身性磷酸二酯酶5和磷酸二酯酶6抑制剂(西地那非)治疗中心性浆液性脉络膜视网膜病变。

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil).

作者信息

Coleman D Jackson, Lee Winston, Daly Suzanne, Breazzano Mark P, Sparrow Janet, Tsang Stephen H

机构信息

Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA.

Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia Stem Cell Initiative, Departments of Ophthalmology, Pathology & Cell Biology, Institute of Human Nutrition, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA.

出版信息

Am J Ophthalmol Case Rep. 2020 Dec 3;21:100998. doi: 10.1016/j.ajoc.2020.100998. eCollection 2021 Mar.

DOI:10.1016/j.ajoc.2020.100998
PMID:33364520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7750488/
Abstract

PURPOSE

Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR).

OBSERVATIONS

In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again rapidly disappeared and did not recur in 5 months of continued therapy.

CONCLUSIONS

AND IMPORTANCE: Systemic sildenafil can cause rapid clearance of CSCR and can augment or replace other treatments.

摘要

目的

研究全身性磷酸二酯酶抑制(西地那非)用于清除中心性浆液性脉络膜视网膜病变(CSCR)的效果。

观察结果

在一名病程较长的CSCR患者中,西地那非使病情迅速缓解。停药(撤药)后,CSCR复发。再次用药时,CSCR再次迅速消失,且在持续治疗的5个月中未复发。

结论及重要性

全身性西地那非可使CSCR迅速清除,可增强或替代其他治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0108/7750488/e059748eac8d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0108/7750488/a9d43eb99453/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0108/7750488/e059748eac8d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0108/7750488/a9d43eb99453/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0108/7750488/e059748eac8d/gr2.jpg

相似文献

1
Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil).采用全身性磷酸二酯酶5和磷酸二酯酶6抑制剂(西地那非)治疗中心性浆液性脉络膜视网膜病变。
Am J Ophthalmol Case Rep. 2020 Dec 3;21:100998. doi: 10.1016/j.ajoc.2020.100998. eCollection 2021 Mar.
2
Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?中浆是否应被列入磷酸二酯酶 5 抑制剂眼部副作用列表?
Ophthalmologica. 2012;227(2):85-9. doi: 10.1159/000333824. Epub 2011 Dec 7.
3
Central serous chorioretinopathy as a cause of vision loss in chronic relapsing inflammatory optic neuropathy.中心性浆液性脉络膜视网膜病变作为慢性复发性炎性视神经病变导致视力丧失的一个原因。
Am J Ophthalmol Case Rep. 2018 Jun 20;11:131-134. doi: 10.1016/j.ajoc.2018.06.013. eCollection 2018 Sep.
4
Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.诊断出患有中心性浆液性脉络膜视网膜病变的患者?接下来该怎么做:中心性浆液性脉络膜视网膜病变的管理
Curr Ophthalmol Rep. 2017 Jun;5(2):141-148. doi: 10.1007/s40135-017-0133-4. Epub 2017 May 8.
5
Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy.联合局部抗炎与口服乙酰唑胺治疗中心性浆液性脉络膜视网膜病变
Optom Vis Sci. 2019 Jul;96(7):500-506. doi: 10.1097/OPX.0000000000001394.
6
Central serous chorioretinopathy due to tadalafil use.使用他达拉非导致的中心性浆液性脉络膜视网膜病变。
Int Ophthalmol. 2013 Apr;33(2):177-80. doi: 10.1007/s10792-012-9646-x. Epub 2012 Oct 14.
7
In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy.在患有特发性中心性浆液性脉络膜视网膜病变的患者中,焦虑评分高于健康对照组,但不随性别或复发性中心性浆液性脉络膜视网膜病变而变化。
Neuropsychiatr Dis Treat. 2015 Apr 28;11:1131-6. doi: 10.2147/NDT.S83216. eCollection 2015.
8
Macular ganglion cell complex thickness in acute and chronic central serous chorioretinopathy.急性和慢性中心性浆液性脉络膜视网膜病变中的黄斑神经节细胞复合体厚度
Int Ophthalmol. 2017 Apr;37(2):409-416. doi: 10.1007/s10792-016-0278-4. Epub 2016 Jun 20.
9
Pattern electroretinography in patients with unilateral acute central serous chorioretinopathy.单侧急性中心性浆液性脉络膜视网膜病变患者的图形视网膜电图。
Clin Exp Optom. 2020 Sep;103(5):656-662. doi: 10.1111/cxo.13016. Epub 2019 Dec 10.
10
A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的多中心长期疗效研究
Am J Ophthalmol. 2016 Oct;170:91-99. doi: 10.1016/j.ajo.2016.07.026. Epub 2016 Aug 9.

引用本文的文献

1
Chronic Central Serous Chorioretinopathy with Pigment Epithelium Detachment Treated with Sildenafil: A Case Report.西地那非治疗伴有色素上皮脱离的慢性中心性浆液性脉络膜视网膜病变:一例报告
Case Rep Ophthalmol. 2022 Sep 19;13(3):692-699. doi: 10.1159/000524992. eCollection 2022 Sep-Dec.

本文引用的文献

1
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.依普利酮治疗活动期、未经治疗超过 4 个月的慢性中心性浆液性脉络膜视网膜病变(VICI)患者:一项随机、双盲、安慰剂对照试验。
Lancet. 2020 Jan 25;395(10220):294-303. doi: 10.1016/S0140-6736(19)32981-2.
2
Central serous chorioretinopathy: Towards an evidence-based treatment guideline.中心性浆液性脉络膜视网膜病变:迈向基于证据的治疗指南。
Prog Retin Eye Res. 2019 Nov;73:100770. doi: 10.1016/j.preteyeres.2019.07.003. Epub 2019 Jul 15.
3
Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration.
血管对西地那非柠檬酸酯在衰老和年龄相关性黄斑变性中的反应。
Sci Rep. 2019 Mar 25;9(1):5049. doi: 10.1038/s41598-019-41509-2.
4
Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial.西地那非治疗黄斑变性:一项两年试验的结果
Ophthalmologica. 2018;240(1):45-54. doi: 10.1159/000486105. Epub 2018 Apr 25.
5
SILDENAFIL CITRATE INDUCED RETINAL TOXICITY-ELECTRORETINOGRAM, OPTICAL COHERENCE TOMOGRAPHY, AND ADAPTIVE OPTICS FINDINGS.枸橼酸西地那非诱导的视网膜毒性——视网膜电图、光学相干断层扫描及自适应光学检查结果
Retin Cases Brief Rep. 2018;12 Suppl 1(Suppl 1):S33-S40. doi: 10.1097/ICB.0000000000000708.
6
Rod metabolic demand drives progression in retinopathies.视网膜代谢需求推动视网膜病变的进展。
Taiwan J Ophthalmol. 2015 Jul-Sep;5(3):105-108. doi: 10.1016/j.tjo.2015.06.002. Epub 2015 Aug 25.
7
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.西地那非治疗慢性阻塞性肺疾病相关重度肺动脉高压的随机对照多中心临床试验。
J Heart Lung Transplant. 2017 Feb;36(2):166-174. doi: 10.1016/j.healun.2016.04.010. Epub 2016 May 7.
8
Bilateral posterior ischemic optic neuropathy associated with the use of Sildenafil for pulmonary hypertension.与使用西地那非治疗肺动脉高压相关的双侧后部缺血性视神经病变。
Can J Ophthalmol. 2016 Jun;51(3):e96-9. doi: 10.1016/j.jcjo.2016.02.005. Epub 2016 Apr 26.
9
Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.中心性浆液性脉络膜视网膜病变:最新发现与新病理生理学假说。
Prog Retin Eye Res. 2015 Sep;48:82-118. doi: 10.1016/j.preteyeres.2015.05.003. Epub 2015 May 27.
10
Age-related macular degeneration: choroidal ischaemia?年龄相关性黄斑变性:脉络膜缺血?
Br J Ophthalmol. 2013 Aug;97(8):1020-3. doi: 10.1136/bjophthalmol-2013-303143. Epub 2013 Jun 5.